title: [Analysis of changes in serum levels of TNF, IL-1 and IL-6 during administration of IL-2. Correlation with clinical response to treatment].
abstract: We have investigated the serum concentrations of TNF, IL-1 and IL-6 in 49 patients with metastatic renal carcinoma receiving interleukin 2 (IL-2) or a combination of IL-2 and interferon alpha (IFN). Our results demonstrate that IL-2 and/or IFN induce an increase of serum concentrations of IL-1 and TNF in 95% and 75% of the patients respectively. Serum IL-6 levels increase in 44% of the patients. Serum concentrations of IL-1 and TNF remain elevated 48 hours after the end of IL-2 infusion. IL-1 and TNF levels are higher in patients receiving a combination of IL-2 and IFN. TNF and IL-1 levels in serum are significantly higher in responders to IL-2 treatment 48 hours after the end of IL-2 infusion. These two biological criteria enable a subgroup of patients with a very low response rate to IL-2 to be defined. The persistent increase of these cytokines in serum indicates a persistent activation of the immune system lasting after the end of IL-2 treatment which could be involved in the antitumor response.
authors.affiliation: Laboratoire d'immunologie, centre Léon-Bérard, Lyon, France.
authors.forename: J Y
authors.initials: JY
authors.lastname: Blay
authors.forename: S
authors.initials: S
authors.lastname: Négrier
authors.forename: V
authors.initials: V
authors.lastname: Combaret
authors.forename: Y
authors.initials: Y
authors.lastname: Merrouche
authors.forename: A
authors.initials: A
authors.lastname: Mercatello
authors.forename: J F
authors.initials: JF
authors.lastname: Moskovtchenko
authors.forename: T
authors.initials: T
authors.lastname: Philip
authors.forename: M
authors.initials: M
authors.lastname: Favrot
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000556:secondary; D004305:Dose-Response Relationship, Drug; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D007375:Interleukin-1 / Q000032:analysis*; D007376:Interleukin-2 / Q000627:therapeutic use*; D015850:Interleukin-6 / Q000032:analysis*; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000556:secondary; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis*
chemical_list: D016898:Interferon-alpha; D007375:Interleukin-1; D007376:Interleukin-2; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha
vernacular_title: Analyse des modifications des concentrations sériques de TNF, d'IL-1 et d'IL-6 au cours de l'administration d'IL-2. Corrélation avec la réponse au traitement.